Literature DB >> 15144747

[Methods to perform economic assessments of health interventions].

Carlos Rubio-Terrés1, José A Sacristán, Xavier Badia, Erik Cobo, Fernando García Alonso.   

Abstract

Mesh：

Year:  2004        PMID： 15144747     DOI： 10.1016/s0025-7753(04)74314-6

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN： 0025-7753            Impact factor:   1.725


× No keyword cloud information.
  5 in total

1.  Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.

Authors:  J M Gil; C Rubio-Terrés; A Del Castillo; P González; F Canorea
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

2.  Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.

Authors:  Miguel Bernardo; Jose Ramón Azanza; Carlos Rubio-Terrés; Javier Rejas
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain.

Authors:  Laura Sánchez-Cenizo; Javier Aller; José Manuel Martínez-Sesmero; Nuria Mir; Carmen Peral; Darío Rubio-Rodríguez; Carlos Rubio-Terrés
Journal:  Clinicoecon Outcomes Res       Date:  2019-07-22

4.  Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.

Authors:  S Grau; J C Pozo; E Romá; M Salavert; J A Barrueta; C Peral; I Rodriguez; D Rubio-Rodríguez; C Rubio-Terrés
Journal:  Clinicoecon Outcomes Res       Date:  2015-10-13

5.  [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].

Authors:  Ginés Escolar-Albaladejo; Gonzalo Barón-Esquivias; José Luis Zamorano; Lourdes Betegón-Nicolás; Cristina Canal-Fontcuberta; Marina de Salas-Cansado; Darío Rubio-Rodríguez; Carlos Rubio-Terrés
Journal:  Aten Primaria       Date:  2016-01-30       Impact factor: 1.137
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.